Difference between revisions of "Part:BBa K4387988:Design"

Latest revision as of 15:54, 8 October 2022

Bivalent Anti-Tumour Necrosis Factor Nanobody (VHH#3E + VHH#12B)

Assembly Compatibility:

10
COMPATIBLE WITH RFC[10]
12
COMPATIBLE WITH RFC[12]
21
COMPATIBLE WITH RFC[21]
23
COMPATIBLE WITH RFC[23]
25
COMPATIBLE WITH RFC[25]
1000
COMPATIBLE WITH RFC[1000]

Design Notes

The amino acid sequence was converted into DNA and then codon optimized for E. coli with the help of the codon optimization tool provided by Integrated DNA Technologies (IDT). The same linker was used as the one described in the patent. [1]

Source

The amino acid sequence was directly taken from the patent mentioned in the description. [1]

References

[1] Silence, Karen, Lauwereys, Marc, De Haard, Hans, et al. "Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor", Int. Publication Number: WO 2004/041862 A2, 21 May 2004

@@ Line 7: / Line 7: @@
 ===Design Notes===
-The amino acid sequence was converted into DNA sequence using ... and then codon optimized for E. coli with the help of the codon optimization tool provided by Integrated DNA Technologies (IDT). The linker between the two nanobodies is taken from the patent. [3]
+The amino acid sequence was converted into DNA and then codon optimized for E. coli with the help of the codon optimization tool provided by Integrated DNA Technologies (IDT). The same linker was used as the one described in the patent. [1]
 ===Source===
+The amino acid sequence was directly taken from the patent mentioned in the description. [1]
-The amino acid sequence was directly taken from the patent mentioned in the description. [3]
 ===References===
+* [1] Silence, Karen, Lauwereys, Marc, De Haard, Hans, et al. "Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor", Int. Publication Number: WO 2004/041862 A2, 21 May 2004